Biogen initiates phase III trial of multiple sclerosis drug
PharmaBiz Wed, 10 Jan 2007 11:40 PM PST
Biogen Idec has initiated the phase III clinical programme of BG-12, an oral fumarate in development for relapsing-remitting multiple sclerosis (MS).

Disease stalls hit-and-run sentence Orlando Sentinel Wed, 10 Jan 2007 12:50 PM PST Multiple sclerosis renders the driver in a fatal accident incompetent,a psychiatrist says. A Volusia County judge wanted to sentence Wendall Maxwell on Monday for fleeing from a fatal crash that killed a young skateboarder.

Couple found dead with their pets after relatives' call to paramedics The Scotsman Wed, 10 Jan 2007 5:43 PM PST MERCY killing debate reopens after author and ill wife found dead on remote isle.

Drug Linked To Increase In Brain Hemorrhage Cases Medical News Today Thu, 11 Jan 2007 0:02 AM PST The rate of brain hemorrhages associated with blood thinning drugs quintupled during the 1990s, according to a study published in the January 9, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology. In people over age 80, the rate increased more than tenfold. [click link for full article]

Women With Migraines More Likely To Have Depression
Medical News Today Thu, 11 Jan 2007 0:02 AM PST
Women with chronic headache, especially migraines, are more likely to be depressed, feel tired, and have a host of other severe physical symptoms, according to a study published in the January 9, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.The study involved 1032 women at headache clinics in five states. [click link for full article]

Biotech Stocks Review: Amphora Sells Oncology Program to Genentech
Seeking Alpha - New York,NY,USA
Biogen Idec (BIIB) began treating patients in a Phase III trial of BG-12, an oral fumarate aimed at relapsing-remitting multiple sclerosis. ...

Horton reports drop in sales
San Diego Union Tribune - San Diego,CA,USA
The studies of BG-12, as the drug is known, are expected to last two years. The drug would be the third in Biogen Idec's portfolio of multiple sclerosis ...

Biogen Idec Initiates Phase III Clinical Program and Genzyme ...
Financial News USA (press release) - La Puente,CA,USA
Biogen Idec (NASDAQ: BIIB) recently announced that it has initiated the Phase III clinical program of BG-12, an oral fumarate in development for ...

Biogen Idec Initiates Phase III Clinical Program Of Oral Compound ...
PipelineReview.com (press release) - Barcelona,Spain
Announced today that it has initiated the Phase III clinical program of BG-12, an oral fumarate in development for relapsing-remitting multiple sclerosis ...
See all stories on this topic

Acorda Therapeutics Elects Barry Greene, COO of Alnylam, to its ...
Business Wire (press release) - San Francisco,CA,USA
Acorda’s lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company's pipeline includes a number of ...
See all stories on this topic